Ownership history in MARSHALL WACE, LLP · 10 quarters on record
This page tracks every 13F SEC filing in which MARSHALL WACE, LLP reported a position in ABCELLERA BIOLOG (ABCL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q3 | UNCHANGED | 47,480 | — | 0% | 0.00% | $239K | $5.03 |
| 2025 Q2 | UNCHANGED | 47,480 | — | 0% | 0.00% | $163K | $3.43 |
| 2025 Q1 | REDUCED | 47,480 | -50,120 | -51.4% | 0.00% | $106K | $2.23 |
| 2022 Q4 | REDUCED | 97,600 | -256,797 | -72.5% | 0.00% | $989K | $10.13 |
| 2022 Q3 | REDUCED | 354,397 | -159,313 | -31.0% | 0.01% | $3.5M | $9.89 |
| 2022 Q2 | ADDED | 513,710 | +175,590 | +51.9% | 0.01% | $5.5M | $10.65 |
| 2021 Q3 | ADDED | 338,120 | +64,841 | +23.7% | 0.03% | $6.8M | $20.04 |
| 2021 Q2 | ADDED | 273,279 | +222,638 | +439.6% | 0.03% | $6.0M | $22.00 |
| 2021 Q1 | REDUCED | 50,641 | -461,769 | -90.1% | 0.01% | $1.7M | $33.96 |
| 2020 Q4 | INITIATED | 512,410 | — | — | 0.11% | $20.6M | $40.24 |
As of 2025 Q4 — sorted by position size